NH TherAguix

At NH TherAguix, our mission is to develop novel nanomedicine solutions applicable to precision radiotherapy in oncology. Our drug candidate AGuIX® is a nanodrug designed to meet the growing medical needs in brain cancer by improving the efficacy and precision of radiotherapy directly within tumors.
As defined by the US Food and Drug Administration, expanded access, sometimes called “compassionate use”, is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

Our goal is to provide access to our investigational drug at the appropriate time and in a manner that is most beneficial to the relevant patient population. We understand that patients, caregivers, or health professionals may wish to have access to our drug candidate before receive regulatory approval, outside the context of a clinical trial. At the present time, we are not making our product available for such pre-approval access. We believe enrollment in our ongoing clinical trial is the safest and most effective way of achieving this goal. We currently have ongoing Phase 1b/2 and Phase 2 clinical trials, in which the investigational drug is added to the standard of care that patients are already be receiving. You can find information about ongoing clinical trials of our drug candidate by visiting www.clinicaltrials.gov and entering “AGuIX” in the “other terms” search box.

NH TherAguix may revisit this policy as we gain additional scientific knowledge about our drug candidate through clinical trial data. Any such changes will be posted to this site.